Abstract
Cerebral angiogenesis is an important process for physiological events such as brain development, but it also occurs in pathological conditions such as stroke. Defined as the generation of new blood vessels from preexisting vasculature, angiogenesis after ischemic stroke is important to limit the subsequent neuronal injury and death, as well as contribute to neurorepair. However, current therapies for ischemic stroke are largely focused on reestablishing uninterrupted blood flow, an important but inherently risky proposition. Furthermore, these therapies can have limited efficacy due to narrow therapeutic windows, and in the case of mechanical clot removal, are invasive procedures. Therefore, better stroke therapies are needed. Since the brain possesses mechanisms, including angiogenesis, to attempt self-repair after injury, it may prove beneficial to look at how such mechanisms are regulated to identify potential targets for new and improved stroke therapies. Perlecan domain V (DV), an endogenous extracellular matrix protein fragment, may represent one such therapeutic target. Key to its appeal is that perlecan DV is endogenously and persistently generated in the brain after stroke and has significant angio-modulatory properties. These, and other properties, have been therapeutically manipulated to improve experimental stroke outcomes, suggesting that DV could represent a promising new stroke therapy. Here we discuss a novel approach to studying DV-mediated angiogenesis in vitro using a coculture model.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American Stroke Association (2013). www.strokeassociation.org
Kahle M, Bix G (2013) Neuronal restoration following ischemic stroke: influences, barriers, and therapeutic potential. Neurorehabil Neural Repair 27(5):469–478
Kim H, Pawlikowska L, Chen Y, Su H, Yang G, Young W (2009) Brain arteriovenous malformation biology relevant to hemorrhage and implication for therapeutic development. Stroke 40:S95–S97
Davis S, Donnan G (2009) 4.5 hours: the new time window for tissue plasminogen activator in stroke. Stroke 40:2266–2267
Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma P (2013) Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698:6–18
Arai K, Lok J, Guo S, Hayakawa K, Xing C, Lo E (2011) Cellular mechanism of neurovascular damage and repair after stroke. J Child Neurol 26(9):1193–1198
Demir R, Ulvi H, Ozel L, Ozdemir G, Guzelcik M, Aygul R (2012) Relationship between plasma metalloproteinase-9 levels and volume and severity of infarct in patients with acute ischemic stroke. Acta Neurol Belg 112:351–356
Ramos-Fernandez M, Bellolio M, Stead L (2011) Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systemic review. J Stroke Cerebrovasc Dis 20(1):47–54
Sumii T, Lo E (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831–836
Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34:2165–2170
Bix G (2013) Perlecan domain V therapy in stroke: a beacon of hope? ACS Chem Neurosci 4(3):370–374
Fan Y, Yang G-Y (2007) Therapeutic angiogenesis for brain ischemia: a brief review. J Neuroimmune Pharmacol 2:284–289
Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown A, Iozzo R (2003) Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 278(19):17491–17499
Arikawa-Hirasawa E, Watanbe H, Takami H, Hassell J, Yamada Y (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23:254–358
Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R (1999) J Cell Biol 147(5):1109–1122
Segev A, Nili N, Strauss B (2004) The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 63:603–610
Deguchi Y, Okutsu H, Okura T, Yamada S, Kimura R, Yuge T, Furukawa A, Morimoto K, Tachikawa M, Ohtsuki S, Hosoya K, Terasaki T (2002) Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J Neurochem 83:381–389
Zoeller J, Whitelock J, Iozzo R (2009) Perlecan regulates developmental angiogenesis by modulating to VEGF-VEGFR2 axis. Matrix Biol 28:284–291
Bix G, Iozzo R (2008) Novel interactions of perlecan: unraveling perlecan’s role in angiogenesis. Microsc Res Tech 71:339–348
Fukuda S, Fini C, Mabuchi T, Koziol J, Eggleston L, de Zoppo G (2004) Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 35:998–1004
Gonzalez E, Reed C, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan D, Iozzo R (2005) BMP-1/tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280(8):7080–7087
Bix G, Fu J, Gonzalez E, Macro L, Barker A, Campbell S, Zutter M, Santoro S, Kim J, Hook M, Reed C, Iozzo R (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J Cell Biol 166(1):97–109
Goyal A, Pal N, Concannon M, Paul M, Doran M, Poluzzi C, Sekiguchi K, Whitelock J, Neill T, Iozzo R (2011) Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a duel receptor antagonism. J Biol Chem 286(29):25947–25962
Willis C, Poluzzi C, Mongiat M, Iozzo R (2013) Endorepellin LG 1/2 domains bind Ig3-5 of VEGFR2 and block proangiogenic signaling by VEGFA in endothelial cells. FEBS J 280(10):2271–2284
McGeer P, Zhu S, Dedhar S (1990) Immunostaining of human brain capillaries by antibodies to very late antigens. J Neuroimmunol 26(3):218–231
Milner R, Hung S, Wang X, Berg G, Spatz M, del Zoppo G (2007) Responses to endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those observed in the neurovascular unit. Stroke 39:191–197
Lee B, Clarke D, Al Ahmad A, Kahle M, Parham C, Auckland L, Shaw C, Fidanboylu M, Orr A, Ogunshola O, Fertala A, Thomas S, Bix G (2011) Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 121(8):3005–3023
Ferrera N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676
Storkebaum E, Carmeliet P (2004) VEGF: a critical player in neurodegeneration. J Clin Invest 113:14–18
Clarke D, Al Ahmad A, Lee B, Parham C, Auckland L, Fertala A, Kahle M, Shaw C, Roberts J, Bix G (2012) Perlecan domain V induces VEGF secretion in brain endothelial cells through integrin αβ51 and ERK-dependent signaling pathways. PLoS One 7(9):e45257
Saini M, Pinteaux E, Lee B, Bix G (2011) Oxygen-glucose deprivation and interleukin-1α trigger the release of perlecan LG3 by cells of neurovascular unit. J Neurochem 119:760–771
Saini M, Bix G (2012) Oxygen-glucose deprivation (OGD) and interleukin-1 (IL-1) differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. Brain Res 1438:65–74
Roberts J, Kahle M, Bix G (2012) Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol 3:155
Al Ahmad A, Lee B, Saini M, Bix G (2011) Perlecan domain V modulates astrogliosis in vitro and after focal cerebral ischemia through multiple receptors and increased nerve growth factor release. Glia 59:1822–1840
Yang R, Bunting S, Ko A, Keyt B, Modi N, Zioncheck T, Ferrara N, Jin H (1998) Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. J Pharmacol Exp Ther 284(1):103–110
Bix G, Clark G (1998) Platelet-activating factor receptor stimulation disrupts neuronal migration in vitro. J Neurosci 18:307–318
Sapatino B, Welsh C, Smith C, Bebo B, Linthicum D (1993) Cloned mouse cerebrovascular endothelial cells that maintain their differentiation markers for factor VIII, low density lipoprotein, and angiotensin-converting enzyme. In Vitro Cell Dev Biol 29A:923–928
Serebriskii I, Castello-Cros R, Lamb A, Golemis E (2008) Fibroblast-derived 3D matrix differentially conditions the growth and drug-responsiveness of human cancer cells. Matrix Biol 27:573–578
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Marcelo, A., Bix, G. (2014). Investigating the Role of Perlecan Domain V in Post-Ischemic Cerebral Angiogenesis. In: Milner, R. (eds) Cerebral Angiogenesis. Methods in Molecular Biology, vol 1135. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0320-7_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0320-7_27
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0319-1
Online ISBN: 978-1-4939-0320-7
eBook Packages: Springer Protocols